Search tips
Search criteria 


Logo of ijpsychHomeCurrent issueInstructionsSubmit article
Indian J Psychiatry. 2001 Jan-Mar; 43(1): 41–45.
PMCID: PMC2955930



The Neuroleptic Malignant Syndrome (NMS) can have a complicated recovery and rechallenging these patients is fraught with risks of recurrence. We examined our data from a sequential case series of NMS over a four-year period for details about treatment, complications and rechallenge. Duration of NMS when treated with one versus two dopamine agonists, and neuroleptic loading rates before NMS and on rechallenge were compared using the chi-square test with correction. Duration of NMS was found to be longer when treated with more than one agonist. The mean loading rate on rechallenge. attempted in six patients, was not found tc be statistically different from that resulting in NMS However, two patients (33%) re-challenged with high-potency neuroleptics at high loading rates experienced partial recurrence. Our findings show no advantage for treating NMS with multiple agents and emphasize the need for a cautious dosing strategy while re-challenging patients with typical neuroleptics.

Keywords: Neuroleptic malignant syndrome, anti-psychotic, adverse reaction

Full Text

The Full Text of this article is available as a PDF (196K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull. 1988;24(1):25–29. [PubMed]
  • Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185–202. [PubMed]
  • Chopra MP, Prakash SS, Raguram R. The neuroleptic malignant syndrome: an Indian experience. Compr Psychiatry. 1999 Jan-Feb;40(1):19–23. [PubMed]
  • Koponen H, Repo E, Lepola U. Long-term outcome after neuroleptic malignant syndrome. Acta Psychiatr Scand. 1991 Dec;84(6):550–551. [PubMed]
  • Levenson JL, Fisher JG. Long-term outcome after neuroleptic malignant syndrome. J Clin Psychiatry. 1988 Apr;49(4):154–156. [PubMed]
  • Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989 Aug;50(8):295–298. [PubMed]
  • Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 1991 Nov;159:709–712. [PubMed]
  • Rothke S, Bush D. Neuropsychological sequelae of neuroleptic malignant syndrome. Biol Psychiatry. 1986 Jul;21(8-9):838–841. [PubMed]
  • Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989 Jan;50(1):18–25. [PubMed]
  • Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986 Apr;73(4):337–347. [PubMed]
  • Spring G, Frankel M. New data on lithium and haloperidol incompatibility. Am J Psychiatry. 1981 Jun;138(6):818–821. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications